Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and others in the Cambridge-London life sciences corridor, and wider local and international ecosystems.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Senior Scientist

Are you passionate about the immune system and its potential to transform therapies? Want to work across diverse, cutting-edge drug discovery projects with Biotech and Pharma clients?

We’re looking for a Senior Scientist to join our growing, collaborative team.

About Us - Nexus BioQuest

We are a specialist preclinical immunology CRO, partnering with Biotech and Pharma to accelerate drug development. Our work spans:

Plant Genome Editing Scientist (Lettuce Transformation and CRISPR)

At LeafyColl, we're developing new lettuce varieties with improved commercial traits using CRISPR-Cas genome editing, and I'm looking for a scientist to take real ownership of this programme.

The role covers the full pipeline: identifying candidate genes, designing editing constructs, Agrobacterium-mediated lettuce transformation, tissue culture and shoot regeneration, through to sequence-confirmed edited plants.

Our primary requirement is proven hands-on success in generating and molecularly validating genome-edited plants, ideally lettuce (Lactuca sativa).

OGT launches first Fusion MRD NGS Panel for AML to expand fusion detection at MRD-level sensitivity

New RNA-based NGS panel helps to detect, analyse and track high-impact AML-associated fusion events across multiple timepoints.

Oxford, UK, October 2026. 

OGT, a leading global provider of genomic research and diagnostic solutions, today announced the launch of the SureSeq™ myPanel Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukaemia (AML). This panel is now available publicly for customers to purchase and implement in their own workflows.

NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051

Stevenage, UK, 21 October 2026 - NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.

NRG5051 is an orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP) that acts through a novel NLRX1-mediated mechanism of action.

Subscribe to